The study was conducted under the supervision of principal investigator Stefan Parent, Centre Hospitalier Universitaire Sainte-Justine, Montreal. All patients received a CR (Fuji FCR 7501S) and an EOS exam for which skin dose was measured at skin level by dosimeters in 13 anatomical areas.

Image quality was assessed following European Guidelines (EUR 16261EN). Results showed 97.2% of exams were considered of equal or better quality with EOS, while dose reduction factors ranked from 2.9 (neck) to 9.2 (iliac crest).

Biospace med said that the EOS targets particularly the diagnosis, follow-up, preoperative assessment and postoperative follow-up of degenerative diseases and bone and joint deformities. EOS allows ultra-low-dose, full-body or localized imaging. It allows three-dimensional (3D) images of the human skeleton as a result of software that reconstructs and models a patient’s bones from just two simultaneous images.

The software also generates 3D measurements (lengths, angles) automatically, and can calculate a broad range of clinical parameters, some of which were hitherto inaccessible, but which are essential to diagnosis and surgical planning. The images and clinical parameters are obtained in standing or seated weight-bearing positions and thus reflect the bone and joint status of the patient’s posture.

Marie Meynadier, CEO of Biospace med, said: “Publication of this landmark study in the preeminent medical journal, Spine, is a key step in recognizing the value of our outstanding EOS technology in providing a solution to the issue of medical irradiation.

“It will fortify our efforts to further establish this revolutionary musculoskeletal imaging modality as a standard of care in orthopedic imaging. EOS is a significant step in the application of the ALARA (As Low As Reasonably Achievable) principle for dose reduction.”